These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36197713)

  • 1. Electronic Health Diary Campaigns to Complement Longitudinal Assessments in Persons With Multiple Sclerosis: Nested Observational Study.
    Sieber C; Chiavi D; Haag C; Kaufmann M; Horn AB; Dressel H; Zecca C; Calabrese P; Pot C; Kamm CP; von Wyl V;
    JMIR Mhealth Uhealth; 2022 Oct; 10(10):e38709. PubMed ID: 36197713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany.
    Ziemssen T; Kurzeja A; Muresan B; Haas JS; Alexander J; Driessen MT
    Neurodegener Dis Manag; 2022 Apr; 12(2):93-107. PubMed ID: 34931528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
    Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
    BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.
    Fischer-Barnicol B; Oechtering J; Kuhle J; Lorscheider J; Kappos L; Derfuss T
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272956
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
    J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
    Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
    Hestvik ALK; Frederiksen JL; Nielsen HH; Torkildsen Ø; Eek C; Huang-Link Y; Haghighi S; Tsai JA; Kant M
    Mult Scler Relat Disord; 2022 Jul; 63():103892. PubMed ID: 35696880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project.
    Favre G; Richardson JL; Moore A; Geissbühler Y; Jehl V; Oliver A; Shechtman S; Diav-Citrin O; Berlin M; De Haan T; Baud D; Panchaud A; Mor A; Sabidó M; de Souza S; Chambers C; van Rijt-Weetink YRJ; van Puijenbroek EP; Yates LM; Girardin F; Stellfeld M; Winterfeld U
    Drug Saf; 2024 Mar; 47(3):227-236. PubMed ID: 38114757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study.
    Kingwell E; Zhang T; Zhu F; Walld R; Carruthers R; Evans C; Marrie RA; Tremlett H
    Expert Opin Drug Saf; 2021 Apr; 20(4):481-487. PubMed ID: 33342303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
    Vieira MC; Conway D; Cox GM; Peeples M; Bensimon AG; Macheca M; Herrera V
    Curr Med Res Opin; 2020 Feb; 36(2):261-270. PubMed ID: 31694401
    [No Abstract]   [Full Text] [Related]  

  • 15. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ponesimod (Ponvory) for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Aug; 63(1630):123-125. PubMed ID: 34550110
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Use of Electronic Well-being Diaries Completed Within a Psychoeducation Program for University Students: Longitudinal Text Analysis Study.
    Linton MA; Jelbert S; Kidger J; Morris R; Biddle L; Hood B
    J Med Internet Res; 2021 Apr; 23(4):e25279. PubMed ID: 33885373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.